ctDNA Surveillance Could Redraw Follow-Up After Curative Colorectal Cancer Surgery
After curative resection for stage I to III colorectal cancer, the central challenge is no longer whether the primary tumor has been removed. The harder question is whether microscopic disease remains, invisible to standard imaging and too small to declare itself clinically until relapse is underway. Circulating tumor DNA has emerged as a biologic readout of that risk, offering a way to detect molecular residual disease long before recurrence becomes radiographically obvious.
This Journal of Clinical Oncology commentary, “Bridging the Gap: From Molecular Residual Disease to Curative Opportunity,” sits squarely in that space. It frames ctDNA-guided surveillance as more than a technical refinement of follow-up schedules; it is a potential reordering of postoperative cancer care around tumor biology rather than calendar-driven clinic visits. The accompanying original report is the Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial, a design that signals how quickly this field is moving from proof-of-concept toward prospective testing in routine postoperative management.
A single postoperative scan can miss what a blood assay may capture over time.
The biologic logic is straightforward. Surgery clears the macroscopic lesion, but not every patient leaves the operating room with the same hidden burden of disease. A blood-based assay that identifies tumor-derived DNA fragments can, in principle, function as a real-time marker of residual cancer cell activity. When ctDNA is absent, surveillance may be able to spare some patients from repeated testing that adds burden without changing management. When ctDNA persists or reappears, the signal may justify earlier investigation, closer observation, or intervention before metastatic spread becomes entrenched.
That promise explains why postoperative surveillance has become one of the most compelling use cases for liquid biopsy in oncology. Standard follow-up after colorectal cancer surgery relies on imaging, laboratory testing, and clinical assessment, yet each of those tools is relatively blunt against microscopic disease. ctDNA offers a more direct measurement of tumor biology, and methylation-based approaches extend that concept by interrogating epigenetic alterations linked to cancer detection. In practical terms, the appeal is not simply earlier detection. It is the possibility of separating patients who still harbor curable molecular disease from those whose recurrence risk may be low enough to justify less intensive surveillance.
The commentary’s title makes that aspiration explicit by linking “molecular residual disease” with “curative opportunity.” That phrasing matters because it captures the narrow window in which postoperative surveillance can influence outcome. If ctDNA detects relapse biology early enough, clinicians may be able to act while disease remains limited. If the assay identifies a truly molecular-only state, it may also prevent unnecessary escalation in patients who have already achieved deep remission. The clinical value lies in both directions: finding the patients who need more and protecting the patients who do not.
Still, any ctDNA strategy has to answer a difficult question that routine surveillance has never had to confront with equal precision: what should happen when the blood test turns positive but imaging remains negative? That scenario is where theory meets bedside ambiguity. A molecular signal without a radiographic target may create pressure to intensify follow-up, repeat testing sooner, or consider preemptive therapy, yet the optimal response depends on how reliably the assay predicts relapse and whether acting on the result changes survival. Without that link, earlier detection risks becoming only earlier uncertainty.
The phase III structure of the FIND trial suggests that the field is now testing exactly those assumptions in a prospective framework. That step is important because observational enthusiasm alone cannot establish that biomarker-guided surveillance improves outcomes meaningful to patients. For a test to move from prognostic interest to clinical utility, it has to alter decisions in a way that improves recurrence detection, treatment timing, or ultimately cure rates without adding unnecessary interventions. The biologic signal is attractive; the clinical pathway still has to prove itself.
Colorectal cancer is a sensible proving ground for that work. The disease has a well-defined postresection surveillance tradition, a substantial recurrence burden in at-risk patients, and a treatment paradigm in which earlier recognition of relapse may influence salvage options. Those features make it easier to test whether a molecular marker can outperform or refine standard surveillance. They also make missteps more visible. If ctDNA-guided monitoring is too sensitive, it could increase testing intensity and patient anxiety without delivering actionable benefit. If it is not sensitive enough, clinicians could be falsely reassured by a negative result.
The commentary also reflects a broader shift in oncology practice: surveillance is no longer viewed as a passive administrative interval between surgery and recurrence. It is becoming an active biologic assay of remission. That shift has consequences for how oncologists counsel patients after resection, how they structure follow-up visits, and how they interpret uncertainty when standard imaging is unrevealing. In a disease where cure depends on catching residual cancer before it declares itself, the timing and meaning of a positive molecular test carry real bedside weight.
For now, the most important unresolved issue is not whether ctDNA can be measured. It can. The question is how strongly a ctDNA-guided strategy changes the course of care after curative resection for nonmetastatic colorectal cancer, and whether that change translates into durable benefit for patients. The phase III FIND trial is designed to answer part of that question. Until those data are fully integrated into practice, ctDNA remains a powerful biologic tool searching for its safest and most effective role in postoperative surveillance.